IL149222A0 - Stable polymorph of n-(3-ethynlamino)-6,7-bis (2-metoxyethoxy)- 4-quinaolinamine hydrochloride, methods of production, and pharmaceutical uses thereof - Google Patents

Stable polymorph of n-(3-ethynlamino)-6,7-bis (2-metoxyethoxy)- 4-quinaolinamine hydrochloride, methods of production, and pharmaceutical uses thereof

Info

Publication number
IL149222A0
IL149222A0 IL14922200A IL14922200A IL149222A0 IL 149222 A0 IL149222 A0 IL 149222A0 IL 14922200 A IL14922200 A IL 14922200A IL 14922200 A IL14922200 A IL 14922200A IL 149222 A0 IL149222 A0 IL 149222A0
Authority
IL
Israel
Prior art keywords
quinaolinamine
metoxyethoxy
ethynlamino
hydrochloride
bis
Prior art date
Application number
IL14922200A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL149222(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of IL149222A0 publication Critical patent/IL149222A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14922200A 1999-11-11 2000-11-09 Stable polymorph of n-(3-ethynlamino)-6,7-bis (2-metoxyethoxy)- 4-quinaolinamine hydrochloride, methods of production, and pharmaceutical uses thereof IL149222A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16490799P 1999-11-11 1999-11-11
US19319100P 2000-03-30 2000-03-30
US20642000P 2000-05-23 2000-05-23
PCT/US2000/031009 WO2001034574A1 (en) 1999-11-11 2000-11-09 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
IL149222A0 true IL149222A0 (en) 2002-11-10

Family

ID=27389075

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14922200A IL149222A0 (en) 1999-11-11 2000-11-09 Stable polymorph of n-(3-ethynlamino)-6,7-bis (2-metoxyethoxy)- 4-quinaolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
IL177827A IL177827A (en) 1999-11-11 2006-08-31 Use of a crystalline polymorph of hydrochloride salt n - (3 - ethinylphenyl) - 7,6 - bite (2 - methoxyethoxy) - 4 - quinazulinamine in combination with gemcitabine in the preparation of pancreatic cancer drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL177827A IL177827A (en) 1999-11-11 2006-08-31 Use of a crystalline polymorph of hydrochloride salt n - (3 - ethinylphenyl) - 7,6 - bite (2 - methoxyethoxy) - 4 - quinazulinamine in combination with gemcitabine in the preparation of pancreatic cancer drugs

Country Status (38)

Country Link
US (1) US6900221B1 (cs)
EP (4) EP3100730A1 (cs)
JP (1) JP4689916B2 (cs)
KR (1) KR100769264B1 (cs)
CN (1) CN100351241C (cs)
AP (1) AP1434A (cs)
AR (1) AR035563A1 (cs)
AT (1) ATE420645T1 (cs)
AU (3) AU784243B2 (cs)
BG (1) BG65880B1 (cs)
BR (1) BR0015544A (cs)
CA (2) CA2632556C (cs)
CL (1) CL2010000616A1 (cs)
CY (1) CY1112671T1 (cs)
CZ (1) CZ303897B6 (cs)
DE (1) DE60041415D1 (cs)
DK (1) DK1233948T3 (cs)
EA (1) EA005318B1 (cs)
ES (1) ES2320408T3 (cs)
GE (1) GEP20053503B (cs)
HK (1) HK1049663B (cs)
HR (1) HRP20020388B1 (cs)
HU (1) HU226857B1 (cs)
IL (2) IL149222A0 (cs)
IS (1) IS2612B (cs)
MA (1) MA25570A1 (cs)
ME (2) ME00328B (cs)
MY (1) MY129348A (cs)
NO (1) NO327082B1 (cs)
NZ (1) NZ518406A (cs)
PL (1) PL223486B1 (cs)
PT (1) PT1233948E (cs)
RS (1) RS51198B (cs)
SI (1) SI1233948T1 (cs)
SK (1) SK286995B6 (cs)
TW (1) TWI249528B (cs)
UA (1) UA74803C2 (cs)
WO (1) WO2001034574A1 (cs)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CA2514575A1 (en) * 2003-01-31 2004-08-12 Teijin Pharma Limited Crystal of (23s)-1.alpha.-hydroxy-27-nor-25-methylenevitamin d3-26,23-lactone and process for producing the same
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1633758B1 (en) * 2003-05-15 2011-11-23 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
KR100753385B1 (ko) 2003-06-10 2007-08-30 에프. 호프만-라 로슈 아게 1,3,4-트리아자-페날린 및 1,3,4,6-테트라아자페날린유도체
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
AU2005249206A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an EGFR-inhibitor
WO2005117887A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
EP1809636A1 (en) * 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
WO2007060691A2 (en) * 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
EP2013218A2 (en) * 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses
CA2654531C (en) 2006-06-09 2014-12-09 University Court Of The University Of Aberdeen Resonance enhanced drilling: method and apparatus
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
SG174774A1 (en) * 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US7977347B2 (en) * 2006-09-11 2011-07-12 Curis, Inc. Quinazoline based EGFR inhibitors
CA2662937A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
PL2068880T3 (pl) 2006-09-18 2012-09-28 Boehringer Ingelheim Int Sposób leczenia raka z mutacjami EGFR
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
EP2077842A2 (en) * 2006-10-31 2009-07-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
US8343950B2 (en) * 2006-12-15 2013-01-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
US8349855B2 (en) * 2007-02-21 2013-01-08 Natco Pharma Limited Polymorphs of erlotinib hydrochloride and method of preparation
CA2682013C (en) * 2007-04-04 2015-06-30 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
EP2173724B1 (en) * 2007-06-22 2012-12-05 ArQule, Inc. Quinazolinone compounds and methods of use thereof
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
BRPI0814542A2 (pt) * 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
US20100136116A1 (en) 2007-08-17 2010-06-03 Hetero Drugs Limited Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
WO2009025873A2 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Processes for the preparation of crystalline forms a, b and pure crystalline form a of erlotinib hcl
US8119616B2 (en) * 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
ES2526718T3 (es) * 2007-09-10 2015-01-14 Curis, Inc. Inhibidores de EGFR basados en sales de tartrato o complejos de quinazolina que contienen un resto que se une al cinc
US7932279B2 (en) * 2007-10-12 2011-04-26 Arqule, Inc. Substituted tetrazole compounds and uses thereof
EP2207561A2 (en) * 2007-10-19 2010-07-21 Pharma Mar, S.A. Improved antitumoral treatments
BRPI0822012A2 (pt) * 2008-01-18 2015-07-21 Natco Pharma Ltd Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
CA2713459A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
WO2009111691A2 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and egfr antagonists
AU2009221120A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
KR20110005828A (ko) * 2008-03-28 2011-01-19 콘서트 파마슈티컬즈, 인크. 퀴나졸린 유도체 및 치료방법
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
AU2009322158A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. RAF inhibitors and their uses
EP2213281A1 (en) 2009-02-02 2010-08-04 Ratiopharm GmbH Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
EP2499118A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
EP2510110A1 (en) 2009-11-13 2012-10-17 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
KR101208956B1 (ko) * 2010-07-15 2012-12-06 주식회사 셀트리온제약 엘로티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
CN103124557A (zh) 2010-07-23 2013-05-29 基因里克斯(英国)有限公司 纯埃罗替尼
CN101914068A (zh) 2010-08-14 2010-12-15 浙江华海药业股份有限公司 一种厄洛替尼碱的新晶型及其制备方法
CN101948441B (zh) * 2010-09-07 2012-07-25 江苏先声药物研究有限公司 一种Erlotinib盐酸盐A晶型的制备方法
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
WO2012068487A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
WO2012068483A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment based on hypoxic status
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
AU2012225693A1 (en) 2011-03-04 2013-09-19 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CN103648500B (zh) 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
WO2012125904A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of egfr
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012135781A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US20140121373A1 (en) 2011-05-03 2014-05-01 Cadila Healthcare Limited Process for preparing stable polymorphic form of erlotinib hydrochloride
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
AU2012301889B2 (en) 2011-08-31 2016-04-21 Genentech, Inc. Diagnostic markers
RU2014110228A (ru) 2011-09-30 2015-11-10 Дженентек, Инк. Диагностические маркеры
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
CN103420922B (zh) * 2012-05-18 2016-08-31 重庆华邦制药有限公司 一种工业化生产盐酸厄洛替尼b型晶的方法
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014118112A1 (en) 2013-01-29 2014-08-07 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EA201591543A1 (ru) 2013-03-15 2016-09-30 Мирна Терапьютикс, Инк. Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
CN104119284A (zh) * 2013-04-28 2014-10-29 广东东阳光药业有限公司 厄洛替尼新晶型及其制备方法
CN103435559B (zh) * 2013-07-03 2015-05-13 山东金城医药化工股份有限公司 盐酸厄洛替尼新晶型及其制备方法
CN103508962B (zh) * 2013-07-03 2016-04-13 山东金城医药化工股份有限公司 盐酸厄洛替尼b晶型的制备方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
CN103980207B (zh) * 2014-04-04 2016-03-09 亿腾药业（泰州）有限公司 一种盐酸厄洛替尼b型晶的合成方法
WO2015169932A1 (en) 2014-05-07 2015-11-12 Pharos Generics Ltd Polymorph purity, monitoring and associated compositions
KR101592258B1 (ko) 2014-06-20 2016-02-05 보령제약 주식회사 제제 및 이의 제조방법
WO2016082879A1 (en) * 2014-11-27 2016-06-02 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
MX394474B (es) 2014-12-24 2025-03-24 Genentech Inc Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
RU2610337C1 (ru) * 2015-12-10 2017-02-09 Индивидуальный предприниматель Михайлов Олег Ростиславович Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP2019059685A (ja) * 2017-09-26 2019-04-18 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
CN109721553A (zh) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 一种高纯度盐酸厄洛替尼的制备方法
WO2019126136A2 (en) 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
JP2022512584A (ja) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 角皮症を処置するためのｅｇｆｒインヒビター
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN119371319A (zh) * 2024-10-25 2025-01-28 安徽尖峰北卡药业有限公司 一种用于埃罗替尼中间体生产工艺及其生产系统

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800039A (en) 1970-10-21 1974-03-26 Mead Johnson & Co Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines
US4139561A (en) 1978-02-27 1979-02-13 Gulf Research & Development Company Novel substituted amino-aromatic acetylenes and their method of preparation
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4216341A (en) 1978-11-06 1980-08-05 Gulf Research & Development Company Selective hydrogenation of certain nitroaromatic hydroxy substituted acetylenes over a heterogeneous RuS2 catalyst
US4219679A (en) 1978-11-06 1980-08-26 Gulf Research & Development Company Selective hydrogenation of nitro groups on nitroaromatic acetylenes using an unsupported cobalt polysulfide catalyst
US4255313A (en) 1979-04-20 1981-03-10 Gulf Oil Corporation Novel end-capped polyimide oligomers
US4281127A (en) 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
US4305751A (en) 1980-04-16 1981-12-15 Gulf Oil Corporation M-Alkynylanilides and use as herbicides
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS6448048A (en) 1987-08-19 1989-02-22 Oki Electric Ind Co Ltd Organic nonlinear optical material and nonlinear optical element
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5214144A (en) 1991-10-07 1993-05-25 Dowelanco Process for the preparation of 4-haloquinazolines
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5256781A (en) 1991-10-24 1993-10-26 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5639881A (en) 1991-11-08 1997-06-17 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
JPH06205969A (ja) 1992-10-13 1994-07-26 Tajima Inc 板状体加熱処理用仕切板とそれを用いた加熱方法
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
KR0144833B1 (ko) 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JP2646995B2 (ja) 1993-01-28 1997-08-27 武田薬品工業株式会社 キノリンまたはキナゾリン誘導体およびそれらを含んでなる医薬
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JPH07126255A (ja) 1993-09-10 1995-05-16 Eisai Co Ltd キナゾリン系化合物
JP3265083B2 (ja) 1993-09-30 2002-03-11 味の素ファルマ株式会社 ２−［２−（置換アミノ）ベンジルチオ］−５，６，７，８−テトラヒドロ−４（３ｈ）−キナゾリノン誘導体
JP3117371B2 (ja) 1993-11-05 2000-12-11 三井化学株式会社 フロベンゾピラン誘導体及びそれらを有効成分とする除草剤
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996003034A1 (en) * 1994-07-27 1996-02-08 Massachusetts Institute Of Technology Method for retroviral vector insertion in fish
JPH09165385A (ja) 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (cs) 1994-11-12 1997-12-01 Zeneca Ltd
JPH08151377A (ja) 1994-11-25 1996-06-11 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
EP0815115B1 (en) 1995-02-14 2003-05-28 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
AU704544B2 (en) 1995-03-14 1999-04-29 Novartis Ag Trisubstituted phenyl derivatives
WO1996030347A1 (en) * 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
DE69519751T2 (de) 1995-04-20 2001-04-19 Pfizer Inc., New York Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
CZ297524B6 (cs) 1995-11-20 2007-01-03 Eli Lilly And Company Sůl bis-indolylmaleimidu, farmaceutický prostředek s jejím obsahem a způsob její přípravy
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
SI0880508T1 (en) 1996-02-13 2003-10-31 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
DK0923585T3 (da) 1996-07-18 2002-07-01 Pfizer Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
JPH1036326A (ja) 1996-07-18 1998-02-10 Fuji Photo Film Co Ltd ３−エチニルアニリン化合物の酸付加塩及び３−エチニルアニリン化合物の精製方法
JPH1036325A (ja) 1996-07-18 1998-02-10 Fuji Photo Film Co Ltd アミノフェニルアセチレン化合物の製造方法
JP2000501423A (ja) 1996-08-23 2000-02-08 ファイザー インク． アリールスルホニルアミノヒドロキサム酸誘導体
US6004967A (en) 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
EP0849264A1 (de) 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
DK0950059T3 (da) 1997-01-06 2004-11-01 Pfizer Cycliske sulfonderivater
KR100317146B1 (ko) 1997-02-03 2001-12-22 데이비드 존 우드 아릴술포닐아미노 히드록삼산 유도체
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
KR20000070923A (ko) 1997-02-11 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐 하이드록삼산 유도체
ES2239393T3 (es) 1997-05-07 2005-09-16 Sugen, Inc. Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa.
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
CN1234880A (zh) * 1997-07-28 1999-11-10 株式会社资生堂 含有合成云母的投影屏
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
CA2330447C (en) * 1998-04-29 2009-06-30 Pfizer Products Inc. N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
US6344455B1 (en) 1998-11-19 2002-02-05 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, and irreversible inhibitor of tyrosine kinases
YU13200A (sh) * 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
CA2403721C (en) 2000-03-20 2009-06-09 Pfizer Products, Inc. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
US9672526B2 (en) 2012-03-13 2017-06-06 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
EA005318B1 (ru) 2004-12-30
EP1233948A1 (en) 2002-08-28
IL177827A (en) 2014-01-30
MEP36308A (en) 2011-02-10
NO20021910D0 (no) 2002-04-23
EP3100730A1 (en) 2016-12-07
SK5812002A3 (en) 2002-09-10
WO2001034574A1 (en) 2001-05-17
AR035563A1 (es) 2004-06-16
EP2292233A2 (en) 2011-03-09
EP2168581A2 (en) 2010-03-31
MA25570A1 (fr) 2002-10-01
PT1233948E (pt) 2009-04-16
AU1762101A (en) 2001-06-06
EP2168581A3 (en) 2010-07-21
CA2632556C (en) 2012-01-03
EA200200546A1 (ru) 2002-12-26
DE60041415D1 (de) 2009-03-05
RS51198B (sr) 2010-12-31
AU784243B2 (en) 2006-02-23
IS2612B (is) 2010-04-15
BG65880B1 (bg) 2010-04-30
US6900221B1 (en) 2005-05-31
TWI249528B (en) 2006-02-21
AP2002002542A0 (en) 2002-06-30
CN100351241C (zh) 2007-11-28
HU226857B1 (hu) 2009-12-28
JP2003523949A (ja) 2003-08-12
NO20021910L (no) 2002-07-01
HRP20020388A2 (en) 2004-06-30
SK286995B6 (sk) 2009-09-07
HK1049663B (en) 2009-06-12
DK1233948T3 (da) 2009-04-27
ATE420645T1 (de) 2009-01-15
AU2006201815B2 (en) 2009-10-01
CA2389333C (en) 2008-09-02
IS6359A (is) 2002-04-24
MY129348A (en) 2007-03-30
ES2320408T3 (es) 2009-05-22
UA74803C2 (uk) 2006-02-15
SI1233948T1 (sl) 2009-06-30
CA2632556A1 (en) 2001-05-17
EP1233948A4 (en) 2004-01-28
HUP0302665A3 (en) 2004-03-29
BR0015544A (pt) 2002-07-23
EP2292233A3 (en) 2011-07-27
AU2009251148A1 (en) 2010-01-21
NO327082B1 (no) 2009-04-20
CY1112671T1 (el) 2016-02-10
AU2006201815A1 (en) 2006-05-25
CN1414954A (zh) 2003-04-30
KR20020063889A (ko) 2002-08-05
NZ518406A (en) 2004-01-30
ME00328B (me) 2011-05-10
CZ303897B6 (cs) 2013-06-12
CZ20022019A3 (cs) 2003-05-14
CA2389333A1 (en) 2001-05-17
HRP20020388B1 (hr) 2013-02-28
EP2168581A9 (en) 2011-07-20
KR100769264B1 (ko) 2007-10-23
BG106761A (bg) 2003-01-31
YU34202A (sh) 2005-06-10
HUP0302665A2 (hu) 2003-12-29
PL355235A1 (en) 2004-04-05
HK1049663A1 (en) 2003-05-23
JP4689916B2 (ja) 2011-06-01
CL2010000616A1 (es) 2011-04-01
PL223486B1 (pl) 2016-10-31
AP1434A (en) 2005-06-20
IL177827A0 (en) 2006-12-31
EP1233948B1 (en) 2009-01-14
GEP20053503B (en) 2005-05-10

Similar Documents

Publication Publication Date Title
IL149222A0 (en) Stable polymorph of n-(3-ethynlamino)-6,7-bis (2-metoxyethoxy)- 4-quinaolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
AU4796700A (en) Ureido-substituted cyclic amine derivatives and their use as drug
IL210823A (en) N - (alkyl-imidazo [5,1-a] pyridine-3-yl) -carboxamides, their history and their pharmaceutical preparations
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
PL367242A1 (en) Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
AP2004003184A0 (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same and methods for their use.
HUP0105136A3 (en) Amide derivatives, process for their preparation and medicaments containing them
HUP0203453A3 (en) Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
AU2002365516A1 (en) Benzamide derivatives, processes for their preparation, and their pharmaceutical use
HUP0303133A3 (en) Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical and process for their preparation
HUP0200572A2 (en) Amine derivatives as protease inhibitors process for their preparation, pharmaceutical compositions containing them and their use
HUP0303729A3 (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals and process for their preparation
EP1438046A4 (en) BENZAMIDE DERIVATIVES OF THIAZOLE AND PHARMACEUTICAL COMPOSITIONS INHIBITING CELL PROLIFERATION, AND METHODS OF USE
GB0017060D0 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
HUP0200996A3 (en) Amine derivatives, pharmaceutical compositions containing them and their use
HUP0302050A3 (en) Pharmaceutical form of administration for peptides, method for its production and use
HUP0401694A3 (en) Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use
PL356911A1 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
IL164903A0 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
PL366381A1 (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives
PT1696913E (pt) Composição farmacêutica de vinflunina destinada à administração parenteral, processo de preparação e utilização
PL359208A1 (en) New derivatives of quinosoline, method of production of new derivatives of quinosoline and pharmaceutical preparations
HUP0300028A3 (en) Thienopyridine derivatives, their production and use and pharmaceutical compositions containing them
AU2002352388A1 (en) N-aroyl cyclic amine derivatives and their use as orxin receptor antagonist
IL160606A0 (en) C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB20 Patent renewed for 20 years